176 related articles for article (PubMed ID: 9433149)
1. Recombinant human granulocyte-macrophage colony-stimulating factor therapy and endogenous plasma GM-CSF, IL-3, IL-4 concentrations in pediatric patients with solid tumors.
Cetingül N; Kütükçüler N; Kantar M; Kavakli K; Nişli G; Cağlayan S; Oztop S
Turk J Pediatr; 1997; 39(4):473-81. PubMed ID: 9433149
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte and granulocyte-macrophage colony-stimulating factors, their receptors and interleukin-3 levels in newborns.
Coşkun M; Kardelen F; Oygür N; Undar L; Savaş A; Yeğin O
Turk J Pediatr; 1997; 39(3):295-301. PubMed ID: 9339107
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
Conran N; Saad ST; Costa FF; Ikuta T
Ann Hematol; 2007 Apr; 86(4):255-61. PubMed ID: 17205286
[TBL] [Abstract][Full Text] [Related]
6. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
7. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
[TBL] [Abstract][Full Text] [Related]
8. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
Lee J; Kim Y; Lim J; Kim M; Han K
Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.
Lissoni P; Fumagalli E; Malugani F; Ardizzoia A; Bucovec R; Tancini G; Gardani GS
J Biol Regul Homeost Agents; 2001; 15(2):163-5. PubMed ID: 11501974
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.
Roth MD; Gitlitz BJ; Kiertscher SM; Park AN; Mendenhall M; Moldawer N; Figlin RA
Cancer Res; 2000 Apr; 60(7):1934-41. PubMed ID: 10766183
[TBL] [Abstract][Full Text] [Related]
12. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
13. Serum granulocyte-macrophage colony-stimulating factor and interleukin-1 levels in patients with repeated and non-repeated pulmonary infections.
Erduran E; Gedik Y; Aslan Y; Değer O; Oren A
Turk J Pediatr; 1997; 39(2):203-11. PubMed ID: 9223918
[TBL] [Abstract][Full Text] [Related]
14. Endogenous pro-inflammatory cytokines in children and adolescents during chemotherapy-induced neutropenia.
Banning U; Mauz-Körholz C; Muhammad Q; Kösser A; Müller AE; Tunn U; Rieske K; Bönig H; Körholz D
Pediatr Hematol Oncol; 2002 Dec; 19(8):561-8. PubMed ID: 12487831
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo.
Bönig HB; Hannen M; Lex C; Wölfel S; Banning U; Nürnberger W; Körholz D; Göbel U
Cancer; 1999 Jul; 86(2):340-8. PubMed ID: 10421271
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-1 and granulocyte-macrophage colony-stimulating factor levels in protein malnourished patients during acute infection.
Aslan Y; Erduran E; Gedik Y; Mocan H; Okten A; Orem A
Cent Afr J Med; 1996 Jun; 42(6):179-84. PubMed ID: 8870317
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
18. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in an intensive treatment program for children with Ewing's sarcoma.
Luksch R; Massimino M; Cefalo G; Lombardi F; Ferrari A; Casanova M; Gandola L; Terenziani M; Spreafico F; Fossati-Bellani F
Haematologica; 2001 Jul; 86(7):753-60. PubMed ID: 11454532
[TBL] [Abstract][Full Text] [Related]
20. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
